Drug Shortage Report for VASOPRESSIN INJECTION, USP
| Report ID | 121651 |
| Drug Identification Number | 02139502 |
| Brand name | VASOPRESSIN INJECTION |
| Common or Proper name | Vasopressin Injection |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | VASOPRESSIN |
| Strength(s) | 20UNIT |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS |
| Packaging size | 20 units/ mL, MD Vial,1 mL |
| ATC code | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2020-08-04 |
| Estimated end date | 2021-01-31 |
| Actual end date | 2021-01-04 |
| Shortage status | Resolved |
| Updated date | 2021-01-26 |
| Company comments | Fresenius Kabi Canada Ltd. regrets to advise that due to manufacturing constraints related to the Active Pharmaceutical Ingredient (API), we will be placing our Vasopressin Injection, 20 units/ mL, 1 mL MD Vials on reduced allocation. Contract customers will be allocated 50% of their historical average monthly volumes, effective August 3, 2020 (UPDATE 09/01/2020) Fresenius Kabi Canada Ltd. regrets to advise that due to manufacturing constraints related to the Active Pharmaceutical Ingredient (API), we will be placing our Vasopressin Injection, 20 units/ mL, MD Vial, 1 mL on reduced allocation. Contract customers will be allocated 25% of their historical average monthly volumes, effective September 1, 2020. UPDATE 12/03: Estimated Availability Date December 21, 2020 UPDATE 12/13: Estimated Availability Date January 2021 (exact date: TBA) UPDATE Fresenius Kabi Canada Ltd. is pleased to advise that replenishment inventories of our Vasopressin Injection 20 units/mL MD Vial 1 mL are expected to be available by January 4, 2021 for the Ontario region and between January 6 – 8, 2021 for all other regions. Fresenius Kabi recognizes the critical need for this product and has been working diligently to resolve the situation and resupply the market as expeditiously as possible. Allocations for Vasopressin Injection will be set at 200% based on historical demand to allow customers to replenish depleted safety stock levels. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v14 | 2021-01-26 | French | Compare |
| v13 | 2021-01-26 | English | Compare |
| v12 | 2020-12-13 | French | Compare |
| v11 | 2020-12-13 | English | Compare |
| v10 | 2020-12-03 | French | Compare |
| v9 | 2020-12-03 | English | Compare |
| v8 | 2020-09-09 | French | Compare |
| v7 | 2020-09-09 | English | Compare |
| v6 | 2020-09-09 | English | Compare |
| v5 | 2020-09-02 | French | Compare |
| v4 | 2020-09-02 | English | Compare |
| v3 | 2020-08-05 | English | Compare |
| v2 | 2020-08-04 | French | Compare |
| v1 | 2020-08-04 | English | Compare |
Showing 1 to 14 of 14